| Literature DB >> 35475099 |
Sachin M Patil1, Eric D Hilker2.
Abstract
Aeromonas hydrophila is a gram-negative (GN) bacillus with an opportunistic potential in immunocompromised patients. They are ubiquitary in fresh and brackish water capable of infecting healthy and immunosuppressed patients. Clinical manifestations vary in healthy hosts compared to immunocompromised patients. Community-acquired bacterial pneumonia (CABP) is an infrequent clinical presentation of A. hydrophila infection, even in immunosuppressed patients. It is also an uncommon cause of nosocomial and drowning-related pneumonia. Although a rare cause of CABP, the clinical course is fulminant with higher mortality due to lower clinical suspicion. Here, we present an immunocompromised 63-year-old Caucasian male with chronic lymphocytic leukemia (CLL) presenting with acute A. hydrophila CABP with septic shock due to absolute neutropenia and lymphopenia.Entities:
Keywords: aeromonas; bacteremia; lymphopenia; neutropenia; pneumonia; septic shock
Year: 2022 PMID: 35475099 PMCID: PMC9018926 DOI: 10.7759/cureus.23345
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Laboratory results during hospitalization.
PCR: polymerase chain reaction, CLL: chronic lymphocytic leukemia, Ig: immunoglobulin, MRSA: methicillin-resistant Staphylococcus aureus, HIV: human immunodeficiency virus
| Parameters | Values |
| White blood cell count (3,500–10,500/mL) | 29,200/mL (1% neutrophils, 98% lymphocytes) (day 1) |
| Absolute neutrophil count (>1,500 cells/mm3) | 292.2 cells/mm3 (day 1) |
| Absolute neutrophil count (>1,500 cells/mm3) | 2,564 cells/mm3 (day 3) |
| Platelets (150,000–450,000/mL) | 109,000/mL (day 1) |
| Creatinine (0.70–1.20 mg/dL) | 1.58 mg/dL (day 1) |
| Troponin T Gen 5 (≤22 ng/L) | 18 ng/L |
| NT-pro brain natriuretic peptide (0–125 pg/mL) | 1,744 pg/mL |
| Fibrinogen (169–444 mg/dL) | 309 mg/dL |
| Lactic acid (0.5–2.2 mmol/L) | 4.8 mmol/L improved to 1.5 mmol/L in the medical intensive care unit (day 1) |
| Procalcitonin (0.0–0.05 ng/mL) | 43.5 ng/mL |
| Respiratory Biofire 2.1 pathogen PCR panel | Negative (including severe acute respiratory syndrome coronavirus 2, |
| Urine analysis | Negative for urinary tract infection |
| Urine Legionella and Streptococcal antigen | Negative |
| Peripheral smear | CLL with neutropenia, thrombocytopenia, and macrocytic anemia along with smudge cells and rare and large lymphocytes with prominent nucleoli seen |
| Tick panel | Negative for ehrlichiosis and anaplasmosis (day 2) |
| Rocky Mountain spotted fever antibody levels | Indicative of prior infection (IgM < 1:64 and IgG = 1:64) (day 2) |
| Quantitative IgG levels (700–1,600 mg/dL) | 643 mg/dL (day 2) |
| MRSA nares | Negative (day 3) |
| CD8 lymphocyte count (145–898 cells/mm3) | 74.30 cells/mm3 (day 4) |
| CD3 lymphocyte count (550–2,271 cells/mm3) | 451 cells/mm3 (day 4) |
| CD4 lymphocyte count (365–1,488 cells/mm3) | 284.7 cells/mm3 (day 4) |
| Syphilis Treponemal antibody serology | Negative (day 4) |
| HIV-1 and HIV-2 serology | Negative (day 7) |
| Acute viral hepatitis panel | Negative (day 7) |
Figure 1Chest X-ray revealed bilateral perihilar patchy and hazy airspace opacities (red arrows).
Figure 2Computed tomography of the chest with contrast axial view revealed bibasilar right greater than left consolidations and ground-glass opacities (red arrows) with subsegmental atelectasis suggestive of pneumonia.
Figure 3Computed tomography of the chest with contrast coronal view revealed bibasilar right greater than left consolidations and ground-glass opacities (red arrows) with subsegmental atelectasis suggestive of pneumonia.
Antimicrobial susceptibility of Aeromonas hydrophila complex.
MIC: minimum inhibitory concentration
| Antimicrobial | MIC interpretation | MIC dilution |
| Amikacin | Susceptible | ≤2 |
| Cefazolin | Resistant | ≥64 |
| Cefepime | Susceptible | ≤1 |
| Cefoxitin | Susceptible | ≤4 |
| Ceftazidime | Susceptible | ≤1 |
| Ciprofloxacin | Susceptible | ≤0.25 |
| Gentamicin | Susceptible | ≤1 |
| Levofloxacin | Susceptible | ≤0.12 |
| Piperacillin/tazobactam | Resistant | ≥128 |
| Trimethoprim/sulfa | Susceptible | ≤20 |